Figure S5 from CRISPR Screens Identify POLB as a Synthetic Lethal Enhancer of PARP Inhibition Exclusively in BRCA-Mutated Tumors

<p>Supplementary Figure S5. Body weight of the animals is not impacted by the treatment with niraparib – related to Figure 6. A) Effect on body weights of animals containing MDA-MB-436 sgIntron or sgPOLB xenografts treated with vehicle and niraparib at 15 mpk once daily for 28 days. Data is represented as % change in body weights until day 28. B) Effect on body weights of animals containing DLD-1 BRCA2 null sgIntron or sgPOLB xenografts treated with vehicle and niraparib at 30 mpk (left) and 60 mpk (right) once daily for 20 days. Data is represented as % change in body weights until day 20.</p>

Authors

Publication Details

Published
2025-09-02
DOI
https://doi.org/10.1158/1535-7163.30028928
Primary Topic
PARP inhibition in cancer therapy
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Figure S5 from CRISPR Screens Identify POLB as a Synthetic Lethal Enhancer of PARP Inhibition Exclusively in BRCA-Mutated Tumors

Brian Doyon, Madhavi Bandi, Tianshu Feng, William D. Mallender et al.
PARP inhibition in cancer therapy
article

Figure S5 from CRISPR Screens Identify POLB as a Synthetic Lethal Enhancer of PARP Inhibition Exclusively in BRCA-Mutated Tumors

Brian Doyon, Madhavi Bandi, Tianshu Feng, William D. Mallender, Robert Tjin Tham Sjin, Jannik N. Andersen, Erik Wilker, Douglas A. Whittington, Alan Huang, Yi Yu, Xuewen Pan, Katherine Lazarides, Shangtao Liu, Hongxiang Zhang, Ashley H. Choi, Justin L. Engel, Binzhang Shen, Samuel R. Meier, Brian J. McMillan, Michele Meseonznik
article en

Abstract

<p>Supplementary Figure S5. Body weight of the animals is not impacted by the treatment with niraparib – related to Figure 6. A) Effect on body weights of animals containing MDA-MB-436 sgIntron or sgPOLB xenografts treated with vehicle and niraparib at 15 mpk once daily for 28 days. Data is represented as % change in body weights until day 28. B) Effect on body weights of animals containing DLD-1 BRCA2 null sgIntron or sgPOLB xenografts treated with vehicle and niraparib at 30 mpk (left) and 60 mpk (right) once daily for 20 days. Data is represented as % change in body weights until day 20.</p>

Openalex Percentile: Top 68%
PARP inhibition in cancer therapy
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Figure S5 from CRISPR Screens Identify POLB as a Synthetic Lethal Enhancer of PARP Inhibition Exclusively in BRCA-Mutated Tumors — Brian Doyon, Madhavi Bandi, et al. · (2025) | TGRS Research Map | TGRS